Market revenue in 2023 | USD 59.3 million |
Market revenue in 2030 | USD 91.6 million |
Growth rate | 6.4% (CAGR from 2023 to 2030) |
Largest segment | Phase iii |
Fastest growing segment | Phase I |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | Novartis AG ADR, Labcorp Holdings Inc, Medpace Holdings Inc, Charles River Laboratories International Inc, Icon PLC, GlaxoSmithKline Consumer Healthcare (GSK CH India), Aurora Innovation Inc Class A, Biogen Inc, IQVIA Holdings Inc, inVentiv Health |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to neurology clinical trials market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 41.15% in 2023. Horizon Databook has segmented the India neurology clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
India contributed to 8.3% of the global clinical trials activity in 2020. The country is observing an upward trend after the slowdown of clinical trial activity in 2013. This is majorly due to regulatory changes by Indian regulatory bodies to mitigate the challenges posed by regulatory uncertainty.
New amendments have been implemented, which have made the approval process faster and in line with the global practices. Moreover, in March 2016, CDSCO set up an online licensing portal named “SUGAM” for registration of medical devices & drugs. This portal has also been extended to pharmaceutical firms to apply & submit clinical trials.
It has also removed restriction of not conducting more than three clinical trials at any given period. The CDSCO has put the responsibility on Ethics Committee to take into consideration the nature & complexity of clinical trials & grant permission accordingly. Such initiatives by regulatory bodies in the country are expected to positively impact the market in India.
Horizon Databook provides a detailed overview of country-level data and insights on the India neurology clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into India neurology clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account